Sign in →

Test Code VIP; SQ: VASPOL Vasoactive Intestinal Polypeptide, Plasma

Reporting Name

Vasoactive Intestinal Polypeptide,P

Useful For

Detecting vasoactive intestinal polypeptide-producing tumors in patients with chronic diarrheal diseases

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Plasma EDTA


Ordering Guidance


 



Specimen Required


Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube: Lavender top (EDTA)

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions: Centrifuge and aliquot plasma into a plastic vial. Freeze immediately.


Specimen Minimum Volume

0.55 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Plasma EDTA Frozen 90 days

Reference Values

<86 pg/mL

Day(s) Performed

Monday, Thursday

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

84586

LOINC Code Information

Test ID Test Order Name Order LOINC Value
VIP Vasoactive Intestinal Polypeptide,P 3125-2

 

Result ID Test Result Name Result LOINC Value
8150 Vasoactive Intestinal Polypeptide,P 3125-2

Clinical Information

Vasoactive intestinal polypeptide (VIP) was originally isolated from porcine small intestine and was recognized by its potent vasodilator activity. This brain/gut hormone has widespread distribution and is present in neuronal cell bodies localized in the central nervous system, digestive, respiratory, and urogenital tracts, and exocrine, thyroid, and adrenal glands. VIP has a wide scope of biological actions. The main effects of VIP include relaxation of smooth muscle (bronchial and vascular dilation), stimulation of gastrointestinal water and electrolyte secretion, and release of pancreatic hormones.

 

Vasoactive intestinal polypeptide-producing tumors are rare; most (90%) are located in the pancreas. Watery diarrhea, hypokalemia, and achlorhydria are key symptoms.

Interpretation

An elevated vasoactive intestinal polypeptide (VIP) may indicate the presence of an enteropancreatic tumor causing hypersecretion of VIP.

 

Vasoactive intestinal polypeptide-producing tumors are unlikely with a 24-hour stool volume below 700 mL.

Method Description

Vasoactive intestinal polypeptide (VIP) enzyme-linked immunosorbent assay is a two-step competitive immunoassay. VIP in the patient sample competes with a biotin-labelled antigen for a limited number of anti-VIP antibody binding sites on the microplate wells during the first incubation. After a wash step to remove unbound and excess material the samples are incubated with a streptavidin anti horseradish peroxidase conjugate to form a biotin conjugate complex. After washing, an enzyme substrate is added and incubated. Following the incubation, the reaction is stopped by addition of a stopping solution. Antibody-analyte complex is detected by absorbance measurement at 450 nm wavelength. The absorbance measured is inversely proportional to the concentration of VIP in the samples and calibrators.(Unpublished Mayo method)

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus OK

Method Name

Enzyme-Linked Immunosorbent Assay (ELISA)

Forms

If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.

Secondary ID

8150